Ibrexafungerp
drug drugOn this page
Also known as MK 3118MK-3118MK-3118 FREE BASEMK3118Scy-078NA
Summary
Ibrexafungerp (CHEMBL4297513) is an approved small molecule (ATC J02AX07); indicated across 11 conditions including vulvovaginal candidiasis and vulvovaginitis.
At a glance
- Status: Approved (max clinical phase 4)
- Modality: Small molecule
- ATC class: J02AX07
- Indications: 11 conditions
- Clinical trials: 13
- Chemistry: 730 Da · C44H67N5O4
Identifiers
Drug identity and classification
| Field | Value |
|---|---|
| ChEMBL ID | CHEMBL4297513 |
| Name | Ibrexafungerp |
| Type | Small molecule |
| Max phase | 4 |
| FDA approved | yes |
| PubChem CID | 46871657 |
| ATC | J02AX07 |
| Molecular formula | C44H67N5O4 |
| Molecular weight | 730 |
| InChIKey | BODYFEUFKHPRCK-ZCZMVWJSSA-N |
SMILES: C[C@H](C(C)C)[C@]1(CC[C@@]2([C@H]3CC[C@H]4[C@]5(COC[C@]4(C3=CC[C@]2([C@@H]1C(=O)O)C)C[C@H]([C@@H]5OC[C@@](C)(C(C)(C)C)N)N6C(=NC=N6)C7=CC=NC=C7)C)C)C
IUPAC name: (1R,5S,6R,7R,10R,11R,14R,15S,20R,21R)-21-[(2R)-2-amino-2,3,3-trimethylbutoxy]-5,7,10,15-tetramethyl-7-[(2R)-3-methylbutan-2-yl]-20-(5-pyridin-4-yl-1,2,4-triazol-1-yl)-17-oxapentacyclo[13.3.3.01,14.02,11.05,10]henicos-2-ene-6-carboxylic acid
Also known as: Ibrexafungerp, MK 3118, MK-3118, MK-3118 FREE BASE, MK3118, Scy-078, SCY-078, IBREXAFUNGERP, NA
Parent form; salt/anhydrous children: CHEMBL4298168
Patent coverage: 61 distinct patent families (143 SureChEMBL compound mentions), from 1 matched compound structure(s). Mentions count patents naming the compound (not distinct inventions), so promiscuous / reference molecules inflate the mention figure — families are the dedup metric.
Targets
Targets
No target linkage available.
Bioactivity
No ChEMBL bioactivity rows at pChembl ≥ 5 (expected for biologics / antibodies).
Target pathways
No target-pathway data for this drug (no mapped target genes).
Indications & clinical
Indications
11 diseases in clinical trials (phase 1–3, investigational — not approved indications). Highest ChEMBL trial phase per disease; a non-cancer approved use is occasionally logged at phase 3 here.
| Disease (in trials) | Phase | MONDO | EFO |
|---|---|---|---|
| vulvovaginal candidiasis | 3 | MONDO:0006014 | EFO:0007543 |
| vulvovaginitis | 3 | MONDO:0007019 | EFO:1001240 |
| candidemia | 3 | MONDO:0044070 | EFO:1001282 |
| allergic bronchopulmonary aspergillosis | 3 | MONDO:0015243 | EFO:0007140 |
| blastomycosis | 3 | MONDO:0005672 | EFO:0007174 |
| coccidioidomycosis | 3 | MONDO:0005706 | EFO:0007211 |
| histoplasmosis | 3 | MONDO:0018312 | EFO:0007310 |
| candidiasis, invasive | 3 | MONDO:0044067 | EFO:1001283 |
| aspergillosis | 2 | MONDO:0005657 | EFO:0007157 |
| fungal infectious disease | 1 | MONDO:0002041 | MONDO:0002041 |
| fungal lung infectious disease | 1 | MONDO:0005766 | EFO:0007278 |
Clinical trials
Total trials: 13.
Phase distribution
| Phase | Trials |
|---|---|
| PHASE3 | 7 |
| PHASE2 | 4 |
| PHASE1 | 2 |
Top trials by phase / activity
| NCT | Phase | Status | Title |
|---|---|---|---|
| NCT03059992 | PHASE3 | COMPLETED | Study to Evaluate the Efficacy and Safety of Ibrexafungerp in Patients With Fungal Diseases That Are Refractory to or Intolerant of Standard Antifungal Treatment |
| NCT03363841 | PHASE3 | COMPLETED | Open-Label Study to Evaluate the Efficacy and Safety of Oral Ibrexafungerp (SCY-078) in Patients With Candidiasis Caused by Candida Auris (CARES) |
| NCT03734991 | PHASE3 | COMPLETED | Efficacy and Safety of Oral Ibrexafungerp (SCY-078) vs. Placebo in Subjects With Acute Vulvovaginal Candidiasis (VANISH 303) |
| NCT03987620 | PHASE3 | COMPLETED | Efficacy and Safety of Oral Ibrexafungerp (SCY-078) vs. Placebo in Subjects With Acute Vulvovaginal Candidiasis |
| NCT04029116 | PHASE3 | COMPLETED | Phase 3 Study of Oral Ibrexafungerp (SCY-078) Vs. Placebo in Subjects With Recurrent Vulvovaginal Candidiasis (VVC) |
| NCT05178862 | PHASE3 | TERMINATED | A Phase 3, Randomized, Double-blind Study for Patients With Invasive Candidiasis Treated With IV Echinocandin Followed by Either Oral Ibrexafungerp or Oral Fluconazole |
| NCT05399641 | PHASE3 | COMPLETED | Ibrexafungerp for the Treatment of Complicated Vulvovaginal Candidiasis |
| NCT02244606 | PHASE2 | COMPLETED | Oral Ibrexafungerp (SCY-078) vs Standard-of-Care Following IV Echinocandin in the Treatment of Invasive Candidiasis |
| NCT02679456 | PHASE2 | COMPLETED | Safety and Efficacy of Oral Ibrexafungerp (SCY-078) vs. Oral Fluconazole in Subjects With Vulvovaginal Candidiasis |
| NCT03253094 | PHASE2 | COMPLETED | Dose-Finding Study of Oral Ibrexafungep (SCY-078) vs. Oral Fluconazole in Subjects With Acute Vulvovaginal Candidiasis |
| NCT03672292 | PHASE2 | TERMINATED | Evaluate Safety and Efficacy of the Coadministration of Ibrexafungerp With Voriconazole in Patients With Invasive Pulmonary Aspergillosis |
| NCT05668429 | PHASE1 | COMPLETED | ADME Study of [14^C]-Ibrexafungerp in Healthy Male Subjects |
| NCT06954493 | PHASE1 | COMPLETED | Pharmacokinetic Study in Healthy Lactating Women Exposed to Ibrexafungerp |
Clinical evidence (CIViC)
No CIViC predictive evidence (expected for non-precision-medicine drugs).
Pharmacology
Pharmacogenomics
No PharmGKB pharmacogenomic data curated for this drug.
Related molecules
Related molecules
No competitor molecules sharing a primary target (ChEMBL phase ≥2 or PubChem drug-class).